Morgan Rubenstein, APRN
Acute Care · North Charleston, SCNPI 1487297420
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 343 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,600 and has fallen 91.7% since, to $216 in 2025. Among acute care clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 343 payments — averaging $23.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$876
- Mallinckrodt Hospital Products Inc.$788
- Boehringer Ingelheim$755
- Sanofi$638
- Regeneron Healthcare Solutions, Inc.$403
- plus $4K from 30 others
What the payments were for
- Food & beverage$7,73695%
- Education$4175%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 57 | $1,039 |
| GSK | 42 | $876 |
| Mallinckrodt Hospital Products Inc. | 24 | $788 |
| Boehringer Ingelheim | 30 | $755 |
| Sanofi | 25 | $638 |
| Regeneron Healthcare Solutions, Inc. | 14 | $403 |
| United Therapeutics Corporation | 16 | $349 |
| Genentech USA, Inc. | 14 | $318 |
| Mylan Specialty L.p. | 17 | $304 |
| Grifols USA, LLC | 15 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $194 |
| Insmed, Inc. | 8 | $185 |
| Boston Scientific | 3 | $168 |
| Electromed, Inc. | 13 | $153 |
| Inari Medical, Inc. | 1 | $146 |
| CSL Behring | 6 | $146 |
| Astellas Pharma US Inc | 3 | $131 |
| ANI Pharmaceuticals, Inc. | 6 | $131 |
| Johnson & Johnson | 1 | $120 |
| Amgen | 5 | $117 |
| Gilead | 5 | $114 |
| Philips North America LLC | 6 | $102 |
| Ipsen Biopharmaceuticals, Inc | 1 | $97 |
| Curonix LLC | 1 | $76 |
| Harmony Biosciences LLC | 3 | $73 |
| Novartis | 3 | $65 |
| Shionogi Inc | 2 | $61 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| Vertex | 2 | $44 |
| Vapotherm Inc | 2 | $43 |
| Pharming Healthcare, Inc. | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Organogenesis Inc. | 1 | $38 |
| Advanced Respiratory, Inc | 1 | $19 |
| Smith+Nephew | 1 | $17 |
| Resmed Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,153 in reported general payments places this provider in the 95th percentile of 339 acute care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 32 | $425,478 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 297 | $277,708 |
| Dupixent PenDupilumab | 54 | $209,567 |
| Dupixent SyringeDupilumab | 16 | $106,516 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 106 | $89,035 |
| NucalaMepolizumab | 12 | $45,148 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $20,674 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $20,570 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $13,151 |
| Spiriva RespimatTiotropium Bromide | 20 | $13,141 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 229 | $8,286 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $6,676 |
| EliquisApixaban | 12 | $6,340 |
| Azithromycin | 89 | $2,520 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $755 | $451,77068 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta | $876 | $364,100378 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,039 | $95,710128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 acute care providers in South Carolina.
Other acute care in North Charleston
- Heather BowersGreenville$94K
- Michael GajewskiColumbia$62K
- Heather NortonMt Pleasant$57K
- Cameron ThomassonSumter$28K
- Sarah MatthewsGreenville$28K
- Micheal BungerColumbia$15K
- Robin TrauflerColumbia$12K
- Susan FunkGreenville$11K
- Linda HentzLexington$10K
- Kylie CapdevilaFlorence$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.